Lead Product(s): LIV-2008
Therapeutic Area: Oncology Product Name: LIV-2008
Highest Development Status: Preclinical Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 14, 2021
Chiome agreed to grant Henlius an exclusive right and license to antibodies targeting human TROP2 and related intellectual property rights to research, develop, manufacture and commercialize the Licensed Products in China.